RxDoctor Payments Data

Antony Anderson, MD

Family Medicine · Midlothian, TXNPI 1851337992

Payments from drug & device makers

$374in general payments, 2019–2025

Across 24 payments — averaging $15.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$95
  • Novo Nordisk$81
  • Pfizer$78
  • Amarin Pharma, Inc.$55
  • AstraZeneca$16
  • Lilly USA, LLC$16
  • plus $31 from 3 others

What the payments were for

  • Speaking & faculty fees$154%
  • Food & beverage$35996%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$374 in reported general payments places this provider in the 45th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$99,431
Medicare patients
216
Services billed
2,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide162$203,714
OzempicSemaglutide78$131,463
JardianceEmpagliflozin51$68,928
MounjaroTirzepatide38$50,777
Tresiba Flextouch U-100Insulin Degludec23$28,042
Tresiba Flextouch U-200Insulin Degludec14$25,297
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$16,408
EliquisApixaban17$16,163
JanuviaSitagliptin Phosphate18$16,139
Breo ElliptaFluticasone/Vilanterol11$6,586
Gabapentin235$4,577
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$4,292
Rosuvastatin Calcium412$4,240
Duloxetine Hcl148$3,202
Atorvastatin Calcium291$3,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$16$254,491200 claims
Novo NordiskOzempic$81$131,46378 claims
PfizerEliquis$78$16,16317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Midlothian

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →